E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
All adult patients with cancer (all cancer types) treated by immune checkpoint inhibitors (anti-PD1, anti-PDL1, anti-CTLA4 monotherapies or combination) and presenting drug-induced myocarditis. There will be no limitation based on gender and upper limit age. |
|
E.1.1.1 | Medical condition in easily understood language |
Adult patients with all cancer types treated by immune checkpoint inhibitors and presenting drug-induced myocarditis |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
to find the lowest dose required to achieve a circulating monocytes CD86RO≥80% within the first week of treatment and sustainably over three weeks |
|
E.2.2 | Secondary objectives of the trial |
- To evaluate the immunological, myocardial and muscular pharmacodynamic effects of 3 different doses of abatacept in the initial phase (first 21 days) of ICI-myocarditis treatment.
- To assess the pharmacokinetic properties of abatacept used in ICI-myocarditis
- Pharmacokinetic / pharmacodynamic (PK-PD) modeling of abatacept in ICI-myocarditis
- To assess the safety of these different doses (pro-tumorigenicity, infections).
- To evaluate long-term effects of abatacept treatment in ICI-myocarditis over months, up to one year |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Age ≥ 18 years old
2. Patients treated with ICI immunotherapy (monotherapy or combination), including anti-PD1, anti-PDL1, anti-CTLA4; and including any type of cancer
3. Definite, probable or possible ICI-induced myocarditis according to the diagnostic criteria of the most recent expert consensus recommendations
4. Severe or corticosteroid-resistant ICI-myocarditis:
- Severe ICI-myocarditis is defined either 1/ by the appearance of an alteration of the LVEF<50% or a wall motion kinetics abnormality, or 2/ by the appearance of ventricular tachycardias or high-grade conductive disorders (atrioventricular block grade 2 or 3) or 3/ by the association with myasthenia gravis-like-syndrome (diplopia, ptosis, diaphragmatic dysfunction, dysarthria, dysphonia, dysphagia).
- Corticosteroid-resistant ICI-myocarditis is defined by the absence of decrease in troponin levels or the appearance/persistence of severity criteria despite receiving prednisone dose ≥1 mg/kg/day for ≥2 days.
5. Signature of informed consent before any trial procedure from the patient or legal representative or the close relative
6. Patients covered by social security regimen (excepting AME) |
|
E.4 | Principal exclusion criteria |
1. Untreated bacterial, fungal, or viral infection
2. Pregnancy, breast-feeding or planning to become pregnant during the study period
3. For women of childbearing age, lack of effective contraception throughout the duration of participation in the study
4. Being treated with abatacept or belatacept within 3 months prior to inclusion
5. Known hypersensitivity to abatacept or belatacept
6. Being treated with anti-thymoglobulin, or alemtuzumab within 6 weeks of the first scheduled dose of abatacept
7. Patient participating to another interventional study (RIPH1 only)
8. People under legal protection measure (tutorship, curatorship or safeguard measures) |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Proportion of patients with CD86RO saturation ≥80% within the first week of treatment and sustainably over three weeks after randomization. CD86RO will be assessed versus baseline levels (one hour before abatacept administration) at the following timepoints: once 1 to 3 hours after, and once 24 to 72 hours after the first, 2nd and 3rd abatacept dose and a last one at Day 21 after the first administration of abatacept. A patient will be considered with a CD86RO saturation ≥80% within the first week of treatment if at least three CD86RO assessments are over 80% until Day 21 after the first administration of abatacept. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
- Quantification of proxies reflecting the resolution of systemic immune activation: % of regulator T-cells CTLA4+, levels of pro and anti-inflammatory cytokines, C-reactive protein levels, % of circulating monocytes expressing PDL1, % of circulating T-cells expressing PD1. There will be assessed versus baseline levels (one hour before abatacept treatment) and at the following timepoints: once 1 to 3 hours after, and once 24 to 72 hours after the first, 2nd and 3rd abatacept dose, then every ten days up to day 90, and then every three months up to a year of follow-up. In case of additional doses of abatacept, these proxies will also be additionally measured one hour before and one to three hours after each dose of abatacept.
- Quantification of the corticosteroid decrease kinetics (total cumulative dose) and the proportion of patients for whom it was necessary to add other immunosuppressants in addition to glucocorticoids to control the disease during the first 21 days and then 90days of the disease : Area under the curve of troponin-T levels; incidence of heart failure (defined as left-ventricular drop below 50%); and incidence of life-threatening cardiac arrhythmias (defined a sustained ≥30 seconds ventricular tachycardia episode, ventricular fibrillation, cardiac arrest, sinus arrest >4 seconds and complete atrio-ventricular block).
- Quantification of proxies reflecting the resolution of myocarditis: troponin-T and -I, CK, NT-proBNP, left ventricular ejection fraction by echocardiography, cardiac inflammation and myocardial edema quantification evaluated by cardiac MRI, arrhythmias and ventricular conductive disorders quantified on electrocardiographic Holter acquisitions; and humoral autoimmunity against the myocardium or the muscles (anti-troponin I and T, anti-myosin, anti-musK, anti-acetylcholine receptor antibodies). The imaging modalities (MRI, echocardiography) will be assessed at least once as soon as possible after admission, 3 months and one year after abatacept start. The holter ECG (48 hours duration) will be assessed at least once as soon as possible after admission, at day 7, day 14, day 21, and at 3 months and one year after abatacept start. The biological parameters will be assessed at admission, then at least every 3 to 4 days during the 21 first days, then every ten days up to day 90 and then every three months up to a year of follow-up
- Quantification of proxies reflecting the involvement and resolution of any associated myositis: muscles MRI, electromyogram, capnography, functional respiratory exploration, diaphragmatic MRI and echography. These modalities will be assessed at least once as soon as possible after admission, 3 months and one year after abatacept start.
- Pharmacokinetic / pharmacodynamic (PK-PD) modeling of abatacept in ICI-myocarditis with determination of the volume of distribution, terminal half-life, clearance, maximum (Cmax) and residual (Cmin) concentration of circulating abatacept and time to Cmax / Cmin (Tmax/Tmin). Modeling of the 50% median effective concentration of abatacept to saturate CD86 receptor on circulating monocytes and to normalize troponin levels. Abatacept circulating levels, ICI circulating levels, troponin-T blood levels and CD86RO on circulating monocytes will be assessed at baseline (one hour before abatacept treatment) and at the following timepoints: once 1 to 3 hours after, and once 24 to 72 hours after the first, 2nd and 3rd abatacept dose, then every ten days up to day 90, and then every three months up to a year of follow-up. In case of additional doses of abatacept, these proxies will also be additionally measured one hour before and one to three hours after each dose of abatacept.
- Quantification of tumor progression by appropriate examination depending on the tumor type (e.g. CT-scan for lung or renal cancer) using the best monitoring work-up used in standard of care. The imaging modalities will be assessed at least once as soon as possible after admission, after 3 months and one year after abatacept start. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.2.4 | Number of treatment arms in the trial | 3 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 9 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 36 |
E.8.9.1 | In the Member State concerned days | |